Eriksson et al. suggested using plasma chromogranin A for monitoring of disease progression in midgut neuroendocrine tumors (NETs) especially in patients with metastatic disease, but not in hindgut NETs, since there was limited evidence to suggest similar applicability [11]. This evidence concerns the gene CHGA and metastatic neoplasm.